AC Immune SA (ACIU) is a world-renowned clinical-stage biopharmaceutical firm specializing in precision medicine for neurological disorders, such as neurodegenerative and neuroinflammatory diseases. The company's approach is driven by a progressive understanding of genetic, epigenetic, and signal transduction cascades in these disorders. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA has spent nearly two decades pushing the boundaries of scientific research to combat complex neurological ailments.
The company's unique strategic approach is rooted in two propriety discovery platforms - SupraAntigenTM and MorphomerTM. These platforms are leveraged to design, discover, and develop groundbreaking therapies, biologics, and vaccines. The company has introduced a diverse pipeline of first-in-class products that have the potential to meaningfully improve the lives of patients suffering from devastating neurological diseases.
AC Immune SA is globally recognized for its disease-modifying treatments targeting critical proteins involved in neurodegeneration, such as Tau and alpha-synuclein. Its anti-Tau and anti-amyloid beta antibodies are some of the most advanced in Alzheimer's disease (AD). The company's Tau-targeted therapies are especially significant, with the scientific community recognizing Tau pathology as a crucial driver of disease progression in AD and other neurodegenerative disorders.
One of AC Immune SA's notable collaborations is with Eli Lilly and Company for the development and potential commercialization of the anti-Tau antibody, semorinemab, in AD. Additionally, a partnership with Roche, namely Genentech, for the anti-Abeta antibody, crenezumab, has yielded promising results. Both partnerships signify the mutual efforts of big pharmaceutical companies and scientific innovators like AC Immune SA to lead the fight against neurological diseases.
Over the years, AC Immune SA has shown relentless dedication to their mission of combating neurological diseases. Besides corporate collaborations, the company actively participates in clinical studies globally, supporting their drug candidates in various phases of clinical trials.
While remaining at the forefront of scientific discovery, AC Immune SA also maintains a strong commitment to corporate transparency and responsible corporate citizenship. The company continuously updates its shareholders and the investment community about its consistent progress and future pathway.
As biopharmaceutical science advances, AC Immune SA’s commitment to usher in a new era of therapeutics for neurological disorders only strengthens. The company continues to make significant strides in its pursuit of successful treatment and prevention strategies for neurodegenerative and neuroinflammatory diseases, thereby placing it as a key player in this crucial area of medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AC Immune's Phase II VacSYn trial for a Parkinson's vaccine, ACI-7104.056, successfully met its primary safety, tolerability, and immunogenicity goals. The study showed that all treated participants developed antibodies against aggregated alpha-synuclein, with detectable levels in cerebrospinal fluid. The company plans further development, including quarterly dosing studies and a larger Part 2 trial, to investigate potential disease-modifying effects.
AC Immune (NASDAQ: ACIU) announced that its investigational Parkinson's drug, ACI-7104, demonstrated 100% antibody response and was safe and well-tolerated in Part 1 of its Phase 2 VacSYn clinical trial. The company plans to refine its development approach and discuss next steps with regulators before moving to an expanded Phase 2 trial to establish clinical activity for entry into Phase 3. Exploratory analyses also showed preliminary evidence of target engagement and positive trends between immunogenicity antibody levels and disease activity measures.
AC Immune has announced positive preliminary results from its phase 1 study of ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome. The study showed the drug was safe, well-tolerated, achieved clear cerebrospinal fluid penetration, and demonstrated dose-dependent inhibition of IL-1beta release. Recruitment has begun for a phase 1b cohort with cardiovascular disease risk patients, with initial results expected by year-end, and further results from the ongoing study anticipated in H1 2027.
AC Immune (ACIU) reported positive interim Phase 1 clinical trial results for ACI-19764, an orally administered drug targeting the NLRP3 inflammasome. The drug demonstrated safety, tolerability, and brain penetration, along with dose-dependent inhibition of IL-1beta release. The trial has advanced to a Phase 1b cohort for patients at risk of cardiovascular disease, with initial findings expected by year-end.
This article identifies several promising penny stocks for August 2026, highlighting AC Immune, Xtra-Gold Resources, and Zion Oil & Gas. Each company is analyzed for its financial health, growth potential, and current market standing, despite some being pre-revenue or currently unprofitable. The selections emphasize companies with strong balance sheets and solid fundamentals in sectors like biopharmaceuticals, gold exploration, and oil and gas.